ReviewCurrent medicinal chemistry2011
Recent developments in protein and cell-targeted aptamer selection and applications.
Review in Current medicinal chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Aptamer Development for SARS-CoV-2 and Omicron Variants Using the Spike Protein Receptor Binding Domain as a Potential Diagnostic Tool and Therapeutic Agent.Biomolecules · 2025Article
- New Insights into Aptamers: An Alternative to Antibodies in the Detection of Molecular Biomarkers.International journal of molecular sciences · 2024Review
- Recent advances in living cell nucleic acid probes based on nanomaterials for early cancer diagnosis.Asian journal of pharmaceutical sciences · 2024Review
- Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles.Molecules (Basel, Switzerland) · 2023Article
- Aptamer-based rapid diagnosis for point-of-care application.Microfluidics and nanofluidics · 2023Review
- Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy.Pharmaceutics · 2022Review
- Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo.Molecules (Basel, Switzerland) · 2022Article
- Molecular probes for cellular imaging of post-translational proteoforms.RSC chemical biology · 2022Review
- ProtSeq: Toward high-throughput, single-molecule protein sequencing via amino acid conversion into DNA barcodes.iScience · 2022Article
- Advances in Design Strategies of Multiplex Electrochemical Aptasensors.Sensors (Basel, Switzerland) · 2021Review
- Discovery and Characterization of Spike N-Terminal Domain-Binding Aptamers for Rapid SARS-CoV-2 Detection.Angewandte Chemie (International ed. in English) · 2021Article
- A DNA Aptameric Ligand of Human Transferrin Receptor Generated by Cell-SELEX.International journal of molecular sciences · 2021Article
- A DNA aptamer recognizing MMP14 forOncology letters · 2019Article
- Selection of a novel DNA aptamer against OFA/iLRP for targeted delivery of doxorubicin to AML cells.Scientific reports · 2019Article
- Selection and characterization of DNA aptamer against glucagon receptor by cell-SELEX.Scientific reports · 2017Article
- Applications of aptamers in targeted imaging: state of the art.Current topics in medicinal chemistry · 2015Review
- Blocking interaction of viral gp120 and CD4-expressing T cells by single-stranded DNA aptamers.The international journal of biochemistry & cell biology · 2014Article
- Selection of aptamers for mature white adipocytes by cell SELEX using flow cytometry.PloS one · 2014Article
- Aptamer-based therapeutics: new approaches to combat human viral diseases.Pharmaceuticals (Basel, Switzerland) · 2013Article
- Aptamers: problems, solutions and prospects.Acta naturae · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Because of their easily modified chemical structures and wide range of targets, aptamers are ideal candidates for various applications, such as biomarker discovery, target diagnosis, molecular imaging, and drug delivery. Aptamers are oligonucleotide sequences that can bind to their targets specifically via unique three dimensional (3-D) structures. Usually, aptamers are obtained from repeated rounds of in vitro or in vivo selection termed SELEX (Systematic Evolution of Ligands by EXponential enrichment), which can generate aptamers with high affinity and specificity for many kinds of targets, such as biomedically important proteins and even cancer cells. In this review, some basic principles and recent developments in the design of SELEX process are discussed, hopefully to provide some guidelines towards performing more efficient aptamer isolation procedures. Moreover, the biomedical and bioanalytical applications of aptamers are further reviewed, based on some smart biochemical modifications of these oligonucleotide structures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.